Rewiring human cellular input-output using modular extracellular sensors.

[1]  Eli J. Fine,et al.  DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.

[2]  Napoleone Ferrara,et al.  VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.

[3]  J. Wess,et al.  Engineering GPCR signaling pathways with RASSLs , 2008, Nature Methods.

[4]  F. Peale,et al.  Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF* , 2006, Journal of Biological Chemistry.

[5]  Xiaoliu Zhang,et al.  Activation of Silenced Cytokine Gene Promoters by the Synergistic Effect of TBP-TALE and VP64-TALE Activators , 2014, PloS one.

[6]  Morgan L. Maeder,et al.  CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.

[7]  Christopher M. Vockley,et al.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.

[8]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[9]  A. Plückthun,et al.  Stability engineering of antibody single-chain Fv fragments. , 2001, Journal of molecular biology.

[10]  B. Levine,et al.  Engineered T cells: the promise and challenges of cancer immunotherapy , 2016, Nature Reviews Cancer.

[11]  Wendell A. Lim,et al.  Cell-Based Therapeutics: The Next Pillar of Medicine , 2013, Science Translational Medicine.

[12]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[13]  G. Barnea,et al.  The genetic design of signaling cascades to record receptor activation , 2008, Proceedings of the National Academy of Sciences.

[14]  A. Kortt,et al.  scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. , 1999, Protein engineering.

[15]  Kelly A. Schwarz,et al.  Modular Extracellular Sensor Architecture for Engineering Mammalian Cell-based Devices , 2014, ACS synthetic biology.

[16]  Kelly A. Schwarz,et al.  Engineering cell-based therapies to interface robustly with host physiology. , 2016, Advanced drug delivery reviews.

[17]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[18]  M. Kalos,et al.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.

[19]  J. P. Ferreira,et al.  Tuning gene expression with synthetic upstream open reading frames , 2013, Proceedings of the National Academy of Sciences.

[20]  O. Boyman,et al.  Interleukin-2: Biology, Design and Application. , 2015, Trends in immunology.

[21]  G. Majumdar,et al.  Accessory cell-independent stimulation of human T cells by streptococcal M protein superantigen. , 1990, Journal of immunology.

[22]  Russell M. Gordley,et al.  Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors , 2016, Cell.

[23]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[24]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[25]  Meagan E. Sullender,et al.  Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation , 2014, Nature Biotechnology.

[26]  T. Copeland,et al.  The P1' specificity of tobacco etch virus protease. , 2002, Biochemical and biophysical research communications.

[27]  Alexandro E. Trevino,et al.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.

[28]  B. Roth,et al.  Generation of Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) Using Directed Molecular Evolution , 2010, Current protocols in neuroscience.

[29]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[30]  Jun Ma,et al.  GAL4-VP16 is an unusually potent transcriptional activator , 1988, Nature.

[31]  Martin Fussenegger,et al.  Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis , 2015, Science Translational Medicine.

[32]  Bo Kara,et al.  The translation of cell-based therapies: clinical landscape and manufacturing challenges. , 2015, Regenerative medicine.

[33]  Ron Weiss,et al.  A platform for rapid prototyping of synthetic gene networks in mammalian cells , 2014, Nucleic acids research.

[34]  Mauricio S. Antunes,et al.  Programmable Ligand Detection System in Plants through a Synthetic Signal Transduction Pathway , 2011, PloS one.

[35]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[36]  C. Eigenbrot,et al.  High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. , 2004, Journal of molecular biology.

[37]  M. Ultsch,et al.  Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab* , 2006, Journal of Biological Chemistry.